Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 114400.0
(-4.75%)
KRW 114400.0
(-4.75%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 84.83 Billion KRW | 12.61% |
| 2022 | 75.33 Billion KRW | -21.96% |
| 2021 | 96.53 Billion KRW | 8.8% |
| 2020 | 88.73 Billion KRW | 3.59% |
| 2019 | 85.65 Billion KRW | 25.34% |
| 2018 | 68.33 Billion KRW | 11.56% |
| 2017 | 61.25 Billion KRW | 12.91% |
| 2016 | 54.25 Billion KRW | 6.47% |
| 2015 | 50.95 Billion KRW | 10.6% |
| 2014 | 46.06 Billion KRW | -1.2% |
| 2013 | 46.62 Billion KRW | 41.87% |
| 2012 | 32.86 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 22.9 Billion KRW | 5.48% |
| 2024 Q1 | 21.5 Billion KRW | -3.23% |
| 2023 Q3 | 21.6 Billion KRW | 4.2% |
| 2023 Q4 | 22.22 Billion KRW | 2.89% |
| 2023 FY | 84.83 Billion KRW | 12.61% |
| 2023 Q1 | 20.36 Billion KRW | 4.87% |
| 2023 Q2 | 20.73 Billion KRW | 1.77% |
| 2022 FY | 75.33 Billion KRW | -21.96% |
| 2022 Q1 | 17.75 Billion KRW | -4.37% |
| 2022 Q2 | 19.28 Billion KRW | 8.64% |
| 2022 Q3 | 18.88 Billion KRW | -2.1% |
| 2022 Q4 | 19.42 Billion KRW | 2.87% |
| 2021 Q3 | 31.59 Billion KRW | 40.44% |
| 2021 Q1 | 23.88 Billion KRW | 263.44% |
| 2021 Q2 | 22.49 Billion KRW | -5.83% |
| 2021 Q4 | 18.56 Billion KRW | -41.24% |
| 2021 FY | 96.53 Billion KRW | 8.8% |
| 2020 Q2 | 20.96 Billion KRW | 4.33% |
| 2020 FY | 88.73 Billion KRW | 3.59% |
| 2020 Q4 | 6.57 Billion KRW | -78.49% |
| 2020 Q3 | 30.55 Billion KRW | 45.75% |
| 2020 Q1 | 20.09 Billion KRW | -27.42% |
| 2019 Q2 | 21.7 Billion KRW | 17.05% |
| 2019 Q1 | 18.53 Billion KRW | -15.8% |
| 2019 FY | 85.65 Billion KRW | 25.34% |
| 2019 Q4 | 27.68 Billion KRW | 13.2% |
| 2019 Q3 | 24.45 Billion KRW | 12.71% |
| 2018 Q2 | 15.92 Billion KRW | 2.8% |
| 2018 Q3 | 16.48 Billion KRW | 3.48% |
| 2018 Q4 | 22.01 Billion KRW | 33.58% |
| 2018 FY | 68.33 Billion KRW | 11.56% |
| 2018 Q1 | 15.49 Billion KRW | 0.32% |
| 2017 Q1 | 14.93 Billion KRW | -8.16% |
| 2017 FY | 61.25 Billion KRW | 12.91% |
| 2017 Q4 | 15.44 Billion KRW | -0.88% |
| 2017 Q2 | 15.67 Billion KRW | 4.94% |
| 2017 Q3 | 15.58 Billion KRW | -0.61% |
| 2016 FY | 54.25 Billion KRW | 6.47% |
| 2016 Q3 | 14.16 Billion KRW | 4.53% |
| 2016 Q4 | 16.26 Billion KRW | 14.86% |
| 2016 Q2 | 13.54 Billion KRW | 1.84% |
| 2016 Q1 | 13.3 Billion KRW | -6.97% |
| 2015 FY | 50.95 Billion KRW | 10.6% |
| 2015 Q3 | 13.23 Billion KRW | 5.87% |
| 2015 Q4 | 14.29 Billion KRW | 8.06% |
| 2015 Q2 | 12.49 Billion KRW | 4.9% |
| 2015 Q1 | 11.91 Billion KRW | -5.93% |
| 2014 Q2 | 11.17 Billion KRW | 5.01% |
| 2014 Q1 | 10.64 Billion KRW | -34.37% |
| 2014 FY | 46.06 Billion KRW | -1.2% |
| 2014 Q4 | 12.66 Billion KRW | 9.4% |
| 2014 Q3 | 11.57 Billion KRW | 3.58% |
| 2013 Q2 | 10.16 Billion KRW | 6.47% |
| 2013 Q3 | 10.69 Billion KRW | 5.15% |
| 2013 Q1 | 9.54 Billion KRW | 0.0% |
| 2013 Q4 | 16.21 Billion KRW | 51.71% |
| 2013 FY | 46.62 Billion KRW | 41.87% |
| 2012 FY | 32.86 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 14.82 Billion KRW | -472.206% |
| ST Pharm Co.,Ltd. | 75.59 Billion KRW | -12.228% |
| ABL Bio Inc. | 65.52 Billion KRW | -29.467% |
| Cellid, Co., Ltd. | 10.97 Billion KRW | -672.966% |